Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 157, Issue -, Pages 1460-1479Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2018.07.073
Keywords
Diabetes; alpha-Glucosidase; Inhibition; QSAR; Xanthone
Categories
Funding
- European Union (FEDER funds) [POCI/01/0145/FEDER/007265]
- National Funds (FCT/MEC, Fundacao para a Ciencia e Tecnologia and Ministerio da Educacao e Ciencia) [PT2020 UID/QUI/50006/2013]
- FCT [UID/QUI/00062/2013]
- Programa Operational Competitividade e Internacionalizacao (COMPETE) [POCI-01-0145-FEDER-029241]
- framework of QREN [NORTE-01-0145-FEDER-000024]
- Fundação para a Ciência e a Tecnologia [UID/QUI/50006/2013, UID/QUI/00062/2013] Funding Source: FCT
Ask authors/readers for more resources
alpha-Glucosidase plays an important role in carbohydrate metabolism and is therefore an attractive therapeutic target for the treatment of diabetes, obesity and other related complications. In the last two decades, considerable interest has been given to natural and synthetic xanthone derivatives in this field of research. Herein, a comprehensive review of the literature on xanthones as inhibitors of alpha-glucosidase activity, their mechanism of action, experimental procedures and structure-activity relationships have been reviewed for more than 280 analogs. With this overview we intend to motivate and challenge researchers (e.g. chemistry, biology, pharmaceutical and medicinal areas) for the design of novel xanthones as multipotent drugs and exploit the properties of this class of compounds in the management of diabetic complications. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available